Emerging role of new transgenic mouse models in glioma research

References

• Wikstrand C J, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res.57(18), 4130–4140 (1997).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Hlatky R, Suki D et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res.11(4), 1462–1466 (2005).
   PubMed Web of Science ®Google Scholar
• Finkelstein SD, Black P, Nowak TP, Hand CM, Christensen S, Finch PW. Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells. Neurosurgery34(1), 136–143 (1994).
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Donahoe J, Brown T, James CD, Perry A. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol. Appl. Neurobiol.26(4), 361–367 (2000).
   PubMed Web of Science ®Google Scholar
• Lau N, Feldkamp MM, Roncari L et al. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J. Neuropathol. Exp. Neurol.59(9), 759–767 (2000).
   PubMed Web of Science ®Google Scholar
• Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J. Natl Cancer Inst.43(6), 1365–1373 (1969).
   PubMed Web of Science ®Google Scholar
• Bogler O, Huang HJ, Cavenee WK. Loss of wild-type p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res.55(13), 2746–2751 (1995).
   PubMed Web of Science ®Google Scholar
• Bogler O, Nagane M, Gillis J, Huang HJ, Cavenee WK. Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro. Cell Growth Differ.10(2), 73–86 (1999).
   PubMedGoogle Scholar
• Yahanda AM, Bruner JM, Donehower LA, Morrison RS. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol. Cell Biol.15(8), 4249–4259 (1995).
   PubMedGoogle Scholar
• Bruner JM, Saya H, Moser RP. Immunocytochemical detection of p53 in human gliomas. Mod. Pathol.4(5), 671–674 (1991).
   PubMed Web of Science ®Google Scholar
• Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res.52(6), 1427–1433 (1992).
   PubMed Web of Science ®Google Scholar
• Nister M, Libermann TA, Betsholtz C et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-α and their receptors in human malignant glioma cell lines. Cancer Res.48(14), 3910–3918 (1988).
   PubMed Web of Science ®Google Scholar
• Westermark B, Heldin CH, Nister M. Platelet-derived growth factor in human glioma. Glia15(3), 257–263 (1995).
   PubMed Web of Science ®Google Scholar
• Smith JS, Wang XY, Qian J et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J. Neuropathol. Exp. Neurol.59(6), 495–503 (2000).
   PubMed Web of Science ®Google Scholar
• Fleming TP, Saxena A, Clark WC et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res.52(16), 4550–4553 (1992).
   PubMed Web of Science ®Google Scholar
• Morrison RS, Yamaguchi F, Saya H et al. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J. Neurooncol.18(3), 207–216 (1994).
   PubMed Web of Science ®Google Scholar
• Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc. Natl Acad. Sci. USA91(2), 484–488 (1994).
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res.51(8), 2164–2172 (1991).
   PubMed Web of Science ®Google Scholar
• Bigner SH, Humphrey PA, Wong AJ et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res.50(24), 8017–8122 (1990).
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Wong AJ, Vogelstein B et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res.48(8), 2231–2238 (1988).
   PubMed Web of Science ®Google Scholar
• Libermann TA, Nusbaum HR, Razon N et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature313(5998), 144–147 (1985).
   PubMed Web of Science ®Google Scholar
• Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl Acad. Sci. USA84(19), 6899–6903 (1987).
   PubMed Web of Science ®Google Scholar
• Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J. Neuropathol. Exp. Neurol.57(2), 122–130 (1998).
   PubMed Web of Science ®Google Scholar
• Henson JW, Schnitker BL, Correa KM et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann. Neurol.36(5), 714–721 (1994).
   PubMed Web of Science ®Google Scholar
• Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res.56(1), 150–153 (1996).
   PubMed Web of Science ®Google Scholar
• Nozaki M, Tada M, Kobayashi H et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-oncology1(2), 124–137 (1999).
   PubMedGoogle Scholar
• He J, Olson JJ, James CD. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res.55(21), 4833–4836 (1995).
   PubMed Web of Science ®Google Scholar
• Ichimura K, Schmidt EE, Goike HM, Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene13(5), 1065–1072 (1996).
   PubMed Web of Science ®Google Scholar
• Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res.54(24), 6321–6324 (1994).
   PubMed Web of Science ®Google Scholar
• Ivanchuk SM, Mondal S, Dirks PB, Rutka JT. The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. J. Neurooncol.51(3), 219–229 (2001).
   PubMedGoogle Scholar
• Swenberg JA, Koestner A, Wechsler W. The induction of tumors of the nervous system with intravenous methylnitrosourea. Lab. Invest.26(1), 74–85 (1972).
   PubMedGoogle Scholar
• Swenberg JA, Koestner A, Wechsler W. The induction of tumors of the nervous system in rats with intravenous methylnitrosourea (MNU). J. Neuropathol. Exp. Neurol.30(1), 122 (1971).
   PubMedGoogle Scholar
• Kleihues P, Lanto, PL, Magee PN. Chemical carcinogenesis in the nervous system. Int. Rev. Exp. Pathol.15, 153–232 (1976).
   PubMedGoogle Scholar
• Aguzzi A, Brandner S, Isenmann S, Steinbach JP, Sure U. Transgenic and gene disruption techniques in the study of neurocarcinogenesis. Glia15(3), 348–364 (1995).
   PubMed Web of Science ®Google Scholar
• Weissenberger J, Steinbach JP, Malin G, Spada S, Rulicke T, Aguzzi A. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene14(17), 2005–2013 (1997).
   PubMed Web of Science ®Google Scholar
• Holland EC, Li Y, Celestino J et al. Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am. J. Pathol.157(3), 1031–1037 (2000).
   PubMed Web of Science ®Google Scholar
• Jacks T, Remington L, Williams BO et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol.4(1), 1–7 (1994).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Romero MI, Ghosh P et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev.15(7), 859–876 (2001).
   PubMedGoogle Scholar
• Macleod KF, Jacks T. Insights into cancer from transgenic mouse models. J. Pathol.187(1), 43–60 (1999).
   PubMed Web of Science ®Google Scholar
• Sauer B. Inducible gene targeting in mice using the Cre/lox system. Methods14(4), 381–392 (1998).
   PubMed Web of Science ®Google Scholar
• Holland EC, Varmus HE. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc. Natl Acad. Sci. USA95(3), 1218–1223 (1998).
   PubMed Web of Science ®Google Scholar
• Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev.12(23), 3675–3685 (1998).
   PubMed Web of Science ®Google Scholar
• Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol.6(3), 217–223; discussion 223–224 (1996).
   PubMed Web of Science ®Google Scholar
• Yoon KS, Lee MC, Kang SS et al. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma. J. Korean Med. Sci.16(4), 481–488 (2001).
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol.7(3), 871–875 (1997).
   PubMedGoogle Scholar
• Bachoo RM, Maher EA, Ligon KL et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell1(3), 269–277 (2002).
   PubMed Web of Science ®Google Scholar
• Ding H, Shannon P, Lau N et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res.63(5), 1106–1113 (2003).
   PubMed Web of Science ®Google Scholar
• Donehower LA, Harvey M, Slagle BL et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature356(6366), 215–221 (1992).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Guignard F, Zhao D et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell8(2), 119–130 (2005).
   PubMed Web of Science ®Google Scholar
• Gomori E, Doczi T, Pajor L, Matolcsy A. Sporadic p53 mutations and absence of ras mutations in glioblastomas. Acta Neurochir. (Wien)141(6), 593–599 (1999).
   PubMedGoogle Scholar
• Tsurushima H, Ohno T, Tsuboi K, Yoshii Y, Meguro K, Nose T. Low incidence of point mutation of N-rasonco gene in human gliomas. No Shinkei Geka23(7), 581–586 (1995).
   PubMedGoogle Scholar
• Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene15(23), 2755–2765 (1997).
   PubMed Web of Science ®Google Scholar
• Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet.25(1), 55–57 (2000).
   PubMed Web of Science ®Google Scholar
• Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC. Ink4–Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res.62(19), 5551–5558 (2002).
   PubMed Web of Science ®Google Scholar
• Uhrbom L, Kastemar M, Johansson FK, Westermark B, Holland EC. Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res.65(6), 2065–2069 (2005).
   PubMed Web of Science ®Google Scholar
• Ding H, Roncari L, Shannon P et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res.61(9), 3826–3836 (2001).
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res.64(19), 6892–6899 (2004).
   PubMed Web of Science ®Google Scholar
• Wang SI, Puc J, Li J et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res.57(19), 4183–4186 (1997).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol.8(21), 1195–1198 (1998).
   PubMed Web of Science ®Google Scholar
• Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH, Baker SJ. Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res.64(21), 7773–7779 (2004).
   PubMed Web of Science ®Google Scholar
• Wei Q, Clarke L, Scheidenhelm DK et al. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res.66(15), 7429–7437 (2006).
   PubMed Web of Science ®Google Scholar
• Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell1(2), 157–168 (2002).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353(19), 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Romer JT, Kimura H, Magdaleno S et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell6(3), 229–240 (2004).
   PubMed Web of Science ®Google Scholar
• Xu S, Gade TP, Matei C et al. In vivo multiple-mouse imaging at 1.5 T. Magn. Reson. Med.49(3), 551–557 (2003).
   PubMed Web of Science ®Google Scholar
• Koutcher JA, Hu X, Xu S et al. MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia4(6), 480–485 (2002).
   PubMed Web of Science ®Google Scholar